DOI: 10.55522/jmpas.V12I1.4232
VOLUME 12 – ISSUE 1 JANUARY - FEBRUARY 2023
Maharani Maharani, Lia Lajuna, Cut Yuniwati, Nora Veri, Sutrisno Sutrisno
Department of Midwifery, Polytechnic of Health-Ministry of Health, Aceh, Indonesia.
Refer this article
Maharani Maharani, Lia Lajuna, Cut Yuniwati, Nora Veri, Sutrisno Sutrisno, 2023. Phaleria macrocarpa for endometriosis treatment a review. Journal of medical pharmaceutical and allied sciences, V 12 - I 1, Pages - 5582 – 5587. DOI: 10.55522/jmpas.V12I1.4232.
ABSTRACT
Around 5—10% women in their productive age could suffer from endometriosis, a condition where viable endometrial tissue is present outside the uterine cavity. This disease could progress into ovarian cancer and infertility with long-lasting chronic pain. Thus, innovation for safe and efficacious management of this disease is urgent. Exploring the abilities of medicinal plants for endometriosis therapy is quite promising. Of which, Phaleria macrocarpa has been suggested as a strong candidate for the therapy. This review begins with explanations of endometriosis; its aetiology and pathobiology. Thereafter, we present the medicinal properties of P. macrocarpa for being anti-inflammatory, anti-angiogenesis, and anti-proliferation. Results from pre-clinical studies and an ongoing trial of P. macrocarpa as a therapy for endometriosis were also discussed in this review. Future study will explore the activity of this plant extracts against hypoxia inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), B-cell lymphoma 2 (Bcl-2), and Bcl-2-associated X protein (BAX).
Keywords:
Anti-angiogenesis, anti-inflammation, anti-proliferation, endometrium, Phaleria macrocarpa